Zobrazeno 1 - 10
of 19
pro vyhledávání: '"R K, Desser"'
Publikováno v:
JAMA. 240(25)
Fifty-four patients with metastatic non-oat-cell bronchogenic carcinoma were treated with cyclophosphamide, doxorubicin hydrochloride (Adriamycin), methotrexate, and procarbazine hydrochloride (CAMP). Eighteen of 51 of these patients with measurable
Publikováno v:
Cancer treatment reports. 60(3)
Publikováno v:
Lancet (London, England). 1(7953)
Publikováno v:
American journal of clinical pathology. 74(6)
A metastasizing fibrous histiocytoma arising in the lung of a patient who received radiation therapy and long-term chemotherapy for malignant lymphoma is presented. Ultrastructural studies revealed fibroblast-like and histiocyte-like cells, cells of
Publikováno v:
Cancer. 45(7)
A retrospective analysis was made of 25 patients with breast cancer treated only with chemotherapy in order to determine the predictive value of technetium-99m bone scanning in determining response to chemotherapy. Whole-body scanning demonstrated bo
Autor:
J D, Bitran, R K, Desser, T R, DeMeester, M, Colman, R, Evans, A, Billings, M, Griem, L, Rubenstein, C, Shapiro, H M, Golomb
Publikováno v:
Cancer treatment reports. 60(9)
Twenty-three patients with metastatic non-oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%)
Publikováno v:
Rational drug therapy. 8(2)
Autor:
P C, Hoffman, H M, Golomb, J D, Bitran, T R, DeMeester, L, Cohen, M L, Griem, J A, Cooksey, U, Mintz, L I, Gordon, R K, Desser, A E, Kinnealey, C A, Sovik
Publikováno v:
Cancer. 46(12)
In the past five years, we have treated 89 patients with small-cell carcinoma of the lung with radiotherapy plus one of three chemotherapy programs. The 24 patients with disease confined to the chest (Stage IIIMO) had an 87% response rate to the comb
Publikováno v:
Cancer. 51(3)
The response to secondary therapy, chemotherapy or hormonal, is examined in 26 patients with adenocarcinoma of breast who failed adjuvant chemotherapy. Response rates to tamoxifen or combination chemotherapy, cyclophosphamide, methotrexate, and 5-FU
Publikováno v:
Blood. 56(5)